Identifying regulatory genetic effects in pluripotent cells provides important insights into disease variants with potentially transient or developmental origins. Combining existing and newlygenerated data, we established a population-scale resource of 1,367 induced pluripotent stem cell lines derived from 948 unique donors, with matched RNA-sequencing (RNA-seq) and genetic information. The sample size of our study allowed us to significantly expand our knowledge of quantitative trait loci (QTL) in pluripotent human cells and their broad trait and disease relevance.
Introduction
Genome-wide association studies (GWAS) have yielded a compendium of genetic variants that are associated with human traits and diseases. However, the majority of these variants are in intergenic regions 1 , and identifying their molecular function remains an ongoing challenge.
Molecular quantitative trait loci (QTL) studies have been performed to systematically identify the function of genetic variants via their effects on molecular intermediates such as gene expression levels. However, existing QTL resources are largely focused on differentiated cell types, including blood [2] [3] [4] and post-mortem collected tissues 5 . In contrast, much less is known about the impact of genetic variants on molecular intermediates in pluripotent cells, which have only recently become accessible via the first population-based iPSC studies with moderate sample sizes [6] [7] [8] [9] [10] . Due to their embryonic-like state, iPSCs can provide unique insights into genetic regulation of expression in cell states that mimic early development, with relevance to diseases that manifest in utero or in transient states throughout development 9, 11, 12 .
We characterized 1,367 iPSC lines from 948 unique donors, collectively analyzed within the "Integrated iPSC QTL" (i2QTL) Consortium, and provide a comprehensive map of expression regulatory variants in human iPSC. We mapped the effects of nearby common genetic variants on five expression phenotypes, identifying cis-QTL at gene-, exon-level and transcript-, splicing-, alternative polyadenylation-ratio (APA). For gene-level, we further quantified the effects of rare and singleton variants, and the effect of distal variants that act in trans (trans-eQTL). Our data are a valuable community resource, uncovering novel regulatory effects that have not previously been described in differentiated cells and tissues. Building on this regulatory map, we functionally explore GWAS signals for over 4,336 trait loci, finding evidence for colocalization with iPSC QTL for traits such as height and BMI, and diseases, such as cancer and coronary artery disease.
Results
Within the i2QTL Consortium we collected previously published and novel data from human iPSC lines (Table S1 & S2), providing genotype and RNA-seq data from a total of 1,367 iPSC lines, derived from 948 unique donors. The data were obtained from five iPSC consortia; iPSCORE 6 (N=206), GENESiPS 10 , (N=85), PhLiPS 7 (N=65), Banovich et al. 8 (N=49) and HipSci 9 , which has been greatly expanded in size for this study (N=543, original study N=166). Additionally, data from the Choi et al 13 study was included as reference, adding a total of 92 samples comprising fibroblast, ESC and iPSC, used as reference (Table S1 & S2).
In order to mitigate technical differences, we uniformly reprocessed all genotype data, considering both genotyping array and whole genome sequencing data, as well as uniformly reprocessed all RNA-seq data (see Methods). Joint multidimensional scaling (MDS) of i2QTL and GTEx 5 (v7) samples revealed a remarkable level of homogeneity between the iPSC studies compared to tissue-to-tissue and between-sample differences observed in GTEx, with the remaining variability in iPSCs being primarily due to differences in sequencing methods between iPSC consortia ( Fig.   1a ). Using samples from Choi et al, we were able to confirm both the minimal processing effects, using the fibroblast lines, and the embryonic-like state of our iPSC lines.
Mapping cis regulatory effects in iPSCs
We mapped cis-QTL, considering proximal (within the gene body +/-250kb) common variants (MAF >1%) and paired-end stranded RNA-seq data available for 936 samples (N=682 donors) of European ancestry (see Methods).
Among 27,046 tested Ensembl genes, we identified at least one cis-eQTL for 18,430 genes (68% of tested; FDR<5% permutation-based, Table S3 , Methods; in the following denoted eGenes), which corresponds to a 2.5 fold increase in the number of eGenes compared to the largest previous cis-eQTL map in iPSCs 9 (Fig. 1b) . Conversely, the vast majority of the eQTL effects (between 62-86%) described in the previous studies were detected in our data (replication defined at nominal P<0.05 with matched effect direction) ( Fig. S1-4) . We also performed iterative eQTL mapping using stepwise regression (see Methods), which identified two or more independent effects for 39.0% of eGenes, with up to 12 independent cis-eQTL for PTGR1 (Fig. S5) .
To gain insights into iPSC-specific regulation, we contrasted our cis-eQTL map with somatic eQTL maps from GTEx 5 tissues and blood eQTL from BIOS 4 . We observed a larger number of eGenes in iPSC as compared to any of the single GTEx tissues ( Fig. 1b-c) , and approximately equal numbers as observed in BIOS, despite the substantially larger sample size of this study (Fig 1b) .
The increase in power to detect eGenes in iPSC is in line with previous results 9, 14 , likely reflecting the homogeneity of the iPSC lines 15 . We identified 994 eGenes without prior evidence for regulatory effects in neither GTEx nor BIOS (methods ; Table S3 ), 117 of which are protein-coding (Fig 1c) . This set of iPSC-specific eGenes are enriched for known cancer genes curated in the COSMIC database (p<2.2×10^-16, 84 novel eGenes are in COSMIC), and we identified eQTL for 7 DECIPHER disease-implicated genes database (Fig 1c) .
We extended the widely considered gene-level eQTL mapping to an extended set of expression phenotypes (transcript-ratio, exon-level, splicing-ratio (sQTL) and APA-ratio) ( Table S4- 7) . To aid comparability, we used the same gene-based test region to test for QTL variants followed by gene-based FDR adjustment (Methods). In aggregate across all five expression phenotypes, this identified genetic effects for of 18, 556 Ensembl genes (FDR<5% permutation-based, Methods ;   Fig 1d) , where 77% of the eGenes discovered in one phenotype were also detected in at least one other expression-phenotypes. Despite this substantial overlap globally, we observed 3,118 genes (9.8% of all tested genes) with an exon-, transcript-, splicing-or APA-QTL but no genelevel eQTL, highlighting the benefits of QTL mapping using multiple expression phenotypes.
Assessment of the pairwise replication between QTL maps at variant level confirmed substantial
sharing of QTL maps between phenotypes with the largest overlap between the exon-level and gene-level effects, and the most distinct QTL identified at APA-ratio (Fig 1E) . 
Mapping large-effect rare variants impacting gene expression
Rare coding and non-coding variants are associated with comparatively larger effects on gene expression than common variants 16, 17 , which contributes to increased disease risk 18, 19 . As the frequency of variants that can be assessed using QTL mapping is limited by sample size, we sought to identify the landscape of rare genetic variants linked to outlying expression profiles of individual genes within iPSCs.
We considered the subset of lines with both RNA-seq and WGS available (N = 425 cell lines after filtering -Methods, Table S2 ), and focused on variants within, or up to 10 kb around, proteincoding and long non-coding RNA genes. Gene expression outliers were defined as the sample with minimum gene expression Z-score (Z-score < -2, under-expression outlier) or maximum gene expression Z-score (Z-score > 2, over-expression outlier) for a given gene. We computed variant burden scores, equivalent to relative risk, across genes and assessed differences in variant burden in outliers compared to non-outliers, aggregating across gnomAD MAF thresholds (both common and rare) and deleterious annotation (CADD -where available). This score was computed separately for gene-level under-expression outliers and over-expression outliers.
Notably, for both SNPs and indels, we observed an enrichment in under-expression outliers for rare (gnomAD MAF 0<MAF<=0.01%), highly-deleterious (CADD>25) variants (5-fold and 40-fold increase in comparison to non-outlier in SNP and indels respectively) (Fig 2A) ( Table S8) . For structural variants (SVs), a 9-fold increase in rare (study MAF 0<=MAF<1%) duplications, and 18fold increase in rare multi-allelic copy number variants (mCNVs), was observed in overexpression outliers compared with non-outliers ( Fig 2B) ( Table S8 ). The findings for SVs agrees with recent consortium findings detailed previously 20 .
To further identify the extent to which the frequency of a variant in the studied population is associated with outliers compared to non-outliers, we computed enrichment scores for singleton SNPs (where a singleton is defined as a SNP not observed in gnomAD (Fig 2C) ). In this way, the full frequency spectrum of SNPs could be studied, from ultra-rare to common. The analysis was repeated for increasing outlier stringency, from Z-score -2 to -6. Singleton, high-CADD SNPs (CADD>25) were found at a 12-fold higher rate in under-expression outliers than non-outliers at a Z-score of Z <-2 (up to 60-fold when Z < -6). The estimate for singleton, high-CADD (CADD>25) SNPs (12-fold increase) is substantially higher than that observed for the next variant bin at the same CADD and Z-score threshold (5-fold increase) (Fig 2A) .
To contextualize these enrichments with somatic tissues, we repeated the outlier analysis for singleton, high-CADD (CADD>25) SNPs in the 35 tissues from GTEx (v7) with 50 or more samples remaining after PEER factor correction 21 and global outlier removal (see Methods) ( Fig   2D) . To control for variation in sample size across tissues, we calculated the enrichment across 10,000 random draws without replacement of equal sample size for each tissue (N samples = 50). In this comparison, iPSC had the greatest enrichment score (median ~9), followed by GTEx fibroblasts (enrichment ~7) and GTEx testis (enrichment ~5) ( Table S9 ). This enrichment was moderately correlated with number of genes expressed in each tissue (Pearson correlation = 0.34); however, when randomly subset to a fixed number of genes across tissues, the maximum median enrichment was still observed for iPSC compared to GTEx tissues (Sup Fig 6) .
Motivated by the hypothesis that rare variants are driving observed gene outlier effects, we chose the class of variants found to have the largest burden scores (i.e. gnomAD singletons, CADD>25 SNPs) and selected the intersection of these variants present in both GTEx and i2QTL samples (N variants = 305) to assess the relative discovery of outlier effects in genes linked with a shared set of rare, deleterious variants. In total, 38 SNPs were identified in outlier samples in iPSC, with the next closest being GTEx skeletal muscle and lung outlier samples (N variants = 15) ( Table   S10 ). Furthermore, 20 of the 38 SNPs identified in iPSC outlier genes were observed in iPSC but not in any of the 35 GTEx tissues selected (i.e. the variants were observed in outlier samples in iPSC only). In GTEx, these variants were associated with an overall median absolute Z-score across tissues of 0.49 (range 0.27-1). Four of these i2QTL-only outlier genes have Developmental Process annotations in Gene Ontology (GO), and six have known OMIM disease associations ( Table 1) . Comparing enrichment for singleton, highly-deleterious (CADD > 25) SNPs in iPSC (panel C, Zscore = -2, dark-green point) against GTEx v7 tissues (adjusting for difference in sample size; Methods). Enrichment score from 10,000 permutations. Enrichment is strongest in iPSC. E. Highest proportion of outlier effects for shared set of rare, deleterious variants (i.e. variants passing thresholds and found in both i2QTL iPSC and GTEx) are in iPSC. To assess the functional relevance of the identified trans-eQTL, we focused on four trans-eQTL hotspots, defined as trans-eVariants, or blocks of trans-eVariants within 250Kb, associated with five or more unique genes. The hotspot with the largest number of downstream genes affected was located near ELF2, a transcription factor linked to reduced proliferation 23 . The hotspot comprises effects of 16 cis-QTL variants affecting ELF2 and other genes around it; the cis-QTL effects could be split-out into three distinct blocks (between block LD < 0.67) ( Fig. 3C) . Variants in the different blocks were linked to multipe cis-QTL types mostly on ELF2, but also to the APA ratio change of NAA15 (Fig. 3D) . Despite moderate LD between these variants, we see a high degree of downstream trans-eGenes sharing between the cis-eVariants (Fig. 3E) , and no effect exclusively mapped to NAA15. The 37 downstream genes were enriched for sequence motifs from the ELF transcription factors, which have a strong sequence resemblance. Significant associations were observed for ELF3, ELF4 and ELF5 (p-adj: 3.3×10^-7, 6.8×10^-5 and 2.2×10^-6 respectively, g:Profiler 24 ), and 20 out of the 37 trans-eGenes were also known match the ELF2 sequence motif. A second hotspot, in cis linked to a CREB3L2 and in trans linked to 8 eGenes, was interesting as we observed an enrichment for the reactome pathway: "ER to Golgi Anterograde Transport" (p-adj<5.6×10^-5), CREB3L2 was previously linked to both the ER and Golgi complex 25 .
We identified 28 trans-eQTL variants linked to GWAS. Among these discoveries, we found trans-eQTL of GWAS variants linked to breast cancer, congenital craniofacial abnormalities, age of menopause and metabolic traits (Supplementary note 1). For example, the most significant trans-eQTL in iPSC linked the expression of NBPF14 to a GWAS hit (rs11249433) on breast cancer;
NBPF14 was previously identified as one of the top mutated genes in breast cancer 26 . The same GWAS variant was also linked to cis-QTL to three genes of which the gene expression (FAM72 27 , RP11-439A17.7 28 ) or DNA-methylation levels (HIST2H2BA 29 ) are themselves directly linked to (breast) cancer. Another interesting example was found for cleft palate, cleft lip and hemifacial microsomia, for which we identified a set of four variants (rs11072494, rs2289187, rs10459648, rs6495117) that are linked to six downstream trans-eGenes (GPR160, SEMA3A, MDFIC, GRIK2, FAM169A and GLB1L3). Among these genes we observed a significant enrichment for the JNK cascade and the MAPK cascade biological processes (g:Profiler p-adj: 1.0×10^-2, 2.1×10^-2 respectively) which are themselves implicated in congenital craniofacial abnormalities 30, 31 .
To assess the replication of trans-eQTL we used the remaining iPSCs from non-European samples (N=187), in which 17% of the effects could be replicated (nominal P<0.05 and matched effect direction; Methods); a replication rate that exceeds chance expectation (median replication rate 5.3% assessed by testing random trans-eQTL pairs (see Methods)). We also sought to replicate our trans association using existing data, however could not directly replicating events in either blood 2 or the GTEx 5 trans-eQTL maps. However, we did identify a set of 12 trans-eQTL SNPs that are in strong LD (LD>0.8) with previously published trans-eVariants, here affecting different genes (Table S12 ). This result is consistent with reports from GTEx showing the difficulty to replicate trans-eQTL effects across tissues 5 . To further assess the robustness of the trans-eQTL, we tested the cross-omic replication of trans-eQTL in DNA-methylation data, available on a subset of the samples (N=572 donors, N=841 lines), finding evidence for cross-omic replication for 27% of the identified trans-eQTL in trans-meQTL and for DNA-methylation (methods). This was higher than expected by chance with median replication rate of trans-meQTL: 15.3 (see Methods). When combined, we find replication evidence for 38% of the identified trans-eQTL.
Within the hotspots we observe increased replication 45.3% versus 25.6%, Fisher exact P-value 0.01 (Table S12 ). 
Colocalization of GWAS signals and molecular QTL
A major opportunity provided by eQTL maps in pluripotent cells is the identification of diseaseassociated variants that colocalize with eQTL, providing evidence for a developmental or transient mechanism. Using a combination of FINEMAP 32 and eCAVIAR 33 (see Method), we systematically assessed colocalization between the presented cis-QTL map, comprised out of QTL on the five QTL types, and a broad range of previously reported genetic associations obtained from diverse GWAS studies (N=350), collected from the Phenome Scanner Database V2 34 , the NHGRI-EBI GWAS catalog 22 , GWAS curated in LocusCompare 35 , and 1,740 traits from the UKBB phase 1
This identified a total of 4,336 significant colocalization events (Methods), linking 608 diseases and phenotypes to 10,794 cis-QTL from the full range of expression phenotypes ( Table S13 ).
The colocalization events covered a broad range of traits and disease, with the largest number of colocalizations linked to physical traits, such as height and BMI, lab-measurements, like bloodcell composition traits, and diseases, such as Crohn's disease, and coronary artery disease (CAD) ( Fig 4A) . Importantly, when restricting our analysis to gene-level eQTL, over 40% of colocalization events are lost. The largest number of eQTL-type specific colocalization events were observed for the exon-level QTL, followed by colocalization events with gene-level and transcript-ratio QTL (Fig 4B) . As an illustration for CAD, 36 out of 93 GWAS loci were found to colocalize with an iPSC QTL, with at least one QTL-type specific colocalization event that would not be detected by any of the remaining QTL types (Sup Fig S7) . Next to the cis-QTL colocalization we also colocalized the trans-eQTL with the GWAS loci, and found amongs others significant overlaps between the ELF2 and CREB3L2 hotspots with height (Supplementary note 1; Table S14 ). Overview of the number of colocalization events for each GWAS, colors correspond to trait categories. B. Colocalization events for each cis-QTL type, displaying the number of GWAS loci with colocalization events that are specific to a given QTL type (light colour; not detected by any other QTL type) or shared with at least one other QTL type (dark colour) which were affected. C. Mean P-values (+/-95% CI) for iPSC outlier-and non-outlier-associated variants available in UKBB GWAS results when stratifying by colocalization posterior probability (CLPP) score. Outlier-associated variants had overall greater effects in the GWAS in which they are also colocalized, compared to matched non-outlier variants, increasing with colocalization probability. D. Plotting outlier-(blue line) and non-outlier-associated (gray lines) variant p-values for basal metabolic rate (UKBB GWAS ID: 23105) against a uniform distribution. Non-outlierassociated variants were chosen randomly to match the number of outlier-associated variants (repeated 10,000 times). Effects of outlier-associated variants were more significant than any non-outlier combination sampled. Integration of transcriptomic data with GWAS summary statistics offered the opportunity to understand the distribution of large-effect rare variants across many diseases and traits. To assess the impact of rare variants on GWAS traits we focused on rare variants linked to iPSC outlier-and non-outlier samples which were available in UKBB Phase 1 GWAS. Given the sample size of large scale GWAS, such as UKBB, rare variants become testable in GWAS. Here we integrated information on gene colocalization and gene outlier gene-expression levels to annotate function to rare variants, not targeted by QTL mapping. We first selected the variants observed within one individual in i2QTL only; for outlier-associated variants, this has the effect of isolating the set of variants putatively driving observed outlier gene expression (i.e. if the same variant was found in both an outlier and non-outlier individual, this would suggest that the variant is less likely to be causing the observed expression aberration). Furthermore, we filtered for variants with a MAF of 0<MAF<=1% from gnomAD and linked to genes with a colocalization CLPP score > 0.
For each outlier variant, we selected a non-outlier variant linked to the same gene and with the condition that the non-outlier variant have a CADD score in a range +/-5 compared to the CADD score of the outlier variant. Given that UKBB Phase 1 GWAS used imputed genotypes from common variants measured via microarray for rare variant calling 37 , the intersection of variants was considerably smaller than the set of donor-specific rare variants in i2QTL. After intersecting these datasets, we found 10,103 outlier-and non-outlier associated variants linked to 779 genes.
From this set of variants, we investigated genes with at least one outlier and one non-outlier variant in/near the gene (N traits = 543) and compared the GWAS p-values from outlier-and nonoutlier-associated variants at different colocalization CLPP cutoffs (Fig 4C) . Genes that colocalized with the QTL results suggest that variation in the gene locus is involved in modulating risk for a given trait. As colocalization CLPP score was increased from CLPP>0 to CLPP>=0.2, we observed overall greater GWAS p-values for outlier-associated variants than non-outlier- we observed an inflation in outlier variant p-values compared to 10,000 random, matched selections of non-outlier variants (Fig 4D) . The top hit was in gene HSD17B12, a gene known to be involved in type 2 diabetes mellitus 38 , and with a CLPP score of 0.29 in the present study ( Fig   4E) . Notably, the outlier variant has one of the largest effect sizes in a 1Mb locus, but the p-value does not pass a statistical significance threshold in conventional GWAS analysis. Overall, we find 48/543 (8.8%) traits with evidence of colocalization (CLPP>=0.01), comprising 58 unique outlierassociated variants.
Discussion
Access to molecular QTL in pluripotent cells provide insights into the spectrum of genetic effects with trait-relevance that can manifest during development and cell differentiation. To maximize the power to identify such QTL, we harmonized existing population-scale iPSC genetic and transcriptome datasets across five studies, and generated additional data. The scale of our resource, with close to a thousand individuals, has enabled the generation of a comprehensive map of cis-QTL across a broad range of expression phenotypes, but also trans-eQTL and rare variant effects that are typically power-limited in smaller studies.
We identified unique cis-QTL on each of the five gene phenotypes we considered in our genetic analysis, finding cis-QTL for a total of 58% of all quantified genes (N=18,556). This includes 994
cis-eGenes that were not previously detected in other tissues and 3,118 cis-QTL genes with QTL that are specific to ratio-or exon-level QTL effects. Next to the cis-QTL we identified 193 trans-eQTL; 24% of the trans-eQTL were driven by ratio-or exon-level cis-eVariants, variants that are mostly not considered for trans-eQTL. Even when a gene-level effect was observed for a trans-eVariant, we observe that 91 (out of 139) of these trans-eQTL are also linked to ratio cis-eQTL.
This shows the existence of trans effects downstream of cis-QTL that do not affect gene expression level but instead act on other gene expression phenotypes.
To assess the impact of rare variants, we analyzed their role in gene expression outliers. Like previous studies in somatic tissues 39 , rare SNP, indel and SV variants were enriched in outliers compared to non-outliers. By comparing iPSC against 35 GTEx tissues, we observed that iPSC provides the greatest power for detecting aberrant gene expression associated with rare, highlyconserved SNPs. Furthermore, when looking at genes where outlier effects were detected in iPSC but not in any GTEx tissue, we find a unique subset of genes important to developmental processes and linked in OMIM to rare developmental disorders, such as the gene PRSS12
(mental retardation) 40 , RASGRP2 (bleeding disorder) 41 and DUOX2 (thyroid dyshormonogenesis) 42 .
The large scale QTL maps on the diverse set of gene expression phenotypes made it possible to generate an extensive colocalization map between the QTL effects and GWAS loci. We were able to annotate over 4,400 GWAS implicated loci (out of the 29,666 assessed loci), originating from over 600 traits, to expression changes. We observe unique colocalized loci to each of the cis-QTL types and a wide range of traits, from physical traits to diseases and lab-measurements. Over 40% of the GWAS colocalized QTL loci are found not to be linked to gene-level eQTLs, highlighting the importance of effects beyond gene expression level. Interestingly, we also observed colocalizations for two of the trans-eQTL hotspots; namely, the hotspots around ELF2
and CREB3L2, which both colocalized with height GWAS signals. Furthermore, we found colocalization for developmental traits, such as congenital craniofacial abnormalities, and cancers. Lastly, by integrating our colocalization results and rare variants linked to expression outliers, we demonstrated prioritization of variants with large impacts on phenotype in the UK Biobank, thereby providing a means for understanding the spectrum of large-effect rare variants associated with a wide range of complex traits and diseases.
Overall, we present the most comprehensive map of genetic regulation of gene-expression in iPSC to date, and demonstrate the use of this map by generating large-scale colocalization between GWAS and iPSC QTL. Here we were able to link both the QTL map as well as the outlier linked rare variants to trait-associated genetic variants, and observe relevance for developmental traits, physical traits and cancer, among multiple others. Large-scale characterization of iPSC presented herein, combined with population-scale cohorts on differentiated tissues previously published 2,4,5 , allows for detailed comparisons of the molecular functions of genetic variants throughout different stages, from a pluripotent to terminally-differentiated tissues. These complementary datasets, will be invaluable in ongoing research efforts such as gene therapies,
by showing a more complete context in which genetic variants and genes function.
The genetic maps and colocalization catalogs generated by the i2QTL consortium form a unique reference catalog, further aiding interpretation of risk variants in a unique cell type relevant for both development, cellular differentiation and cancer research. We expect that the genetic maps presented here, in ongoing combination with GWAS results will reveal the molecular underpinnings of genetic disease and traits manifesting during early-development.
Online Methods

Dataset information
Within the "Integrated iPSC QTL" (i2QTL) consortium we reanalyzed iPSC data originating from five different studies. Below a short description is given on each of the analyzed studies, in table S1 the references to the data sources are given.
HipSci
The Human Induced Pluripotent Stem Cells Initiative (HipSci) 9 where the LCLs are originally derived from, for this we focused on the array genotypes to match the other datasets.
Genotyping information
Array based genotyping Genotyping information for the individual studies was generated as described in the original publications referenced above. For the QTL analyses the genotyping information as generated by genotyping arrays are used and human genome assembly GRCh37 was used. The genotype information was imputed and phased per sample using IMPUTE2 v2.3.1 49 Figure S8) . We chose to use 40 components to predict the super-population, as this was the optimal number based on re-assigning the 1000G samples back to their original super-populations. (Table S1 ). Depending on the availability of data from each source, we started the reprocessing with CRAM, BAM or FASTQ files. To ensure uniform processing of all samples, the CRAM and BAM files were first transformed to FASTQ files. The reads in the FASTQ files were trimmed to remove adapters and low quality bases (using Trim Galore! [55] [56] [57] ). Next, trimmed reads were alignment using STAR (version: 020201) 58 , using the twopass alignment mode and the default parameters as proposed by ENCODE (c.f. STAR manual).
Whole genome sequencing
All alignments were relative to the GRCh37 reference genome and Ensembl 75 genome annotations 59 . Based on the quality controlled aligned reads we quantified gene-level information on all samples. For the paired-end stranded data we also quantified transcript-ratios, exon-level, alternative polyadenylation ratios and splicing-ratios.
Gene-level RNA expression was quantified from the STAR alignments using featureCounts (v1.6.0) 60 , which was applied to the primary alignments using the "-B" and "-C" options in stranded mode if applicable, using the Ensembl 75 GTF file. In case multiple RNA-seq runs per iPSC line were generated these were summed to one set of gene-counts per iPSC line. Read counts per iPSC line were normalized for gene length and the edgeR 61 normalized total expression count per sample, yielding corrected transcript per million counts (TPM). Using the same setup exon expression level were quantified. We chose to first do a strand-specific merge of overlapping exons and quantified these meta-exons as one entity. Subsequent normalization is the same as for the feature-count derived gene information.
To facilitate a comparison to GTEx v7 5 a second gene-level quantification was performed. The STAR aligned BAMs were used to quantify gene-level information using RNA-SeQC 62 (v. 1.1.8) with the gencode v19 annotation, matched to the GTEx annotation. This limited the quantification differences to only read-QC and alignment. This RNA-SeQC quantification was used only when comparing the i2QTL data to GTEx tissues.
Transcript ratios were quantified by determining transcript isoform levels using Salmon 63 (version: 0.8.2). The Salmon transcript database was built based on transcript information from Ensembl 75. Salmon directly uses the QCed FASTQ data; in the transcript quantification "--seqBias", "--gcBias" and "VBOpt" options were used. The transcript count quantification as returned by Salmon were normalized as described for the gene-level quantification using feature count information. Subsequently, we transformed the transcript levels to ratios per gene, by dividing the count of an individual transcript by the transcript sum per gene.
Alternative polyadenylation (APA) quantification was performed following a similar approach to that used in Zhernakova et al 4 . In brief: first, overlapping 3'UTRs for transcript isoforms from the same gene were merged by taking the union of overlapping regions, such that the set of 3'UTRs for each gene was a set of disjoint genomic regions. Next, these regions were extended by considering the most distal available polyadenylation site for each 3'UTR region, as present in the APADB 64 . For each 3'UTR, the set of alternative polyadenylation sites within that region were identified by taking the union of all annotated APA sites from the APADB, in addition to the annotated end of the 3'UTR given by the Ensembl annotation. These APA sites then subdivide each 3'UTR into a set of windows. The depth of RNA-seq in each window was then computed by using the samtools bedcov function. Finally, the read depth in each window was expressed as a fraction of read depth in the window immediately upstream.
Lastly, we quantified splicing levels using leafcutter 65 (v0.2.8) . Quantifications were of spliceevents are calculated as described in the leafcutter manual. First the junction reads are extracted from the BAM files, after which leafcutter clusters junction reads into introns. Subsequently the intron counts are transformed into ratios per cluster and we linked the intron locations to genes.
RNA quality control
After feature quantification low quality RNA-seq samples were filtered out by applying filters on both Picard 66 and VerifyBamID 67 quality measures as well as gene expression levels. We defined high quality samples as those with > 15 million reads, > 30% coding bases, > 65% coding mRNA bases, a duplication rate lower than 75%, Median 5' bias below 0.4, a 3' bias below 4, a 5' to 3' bias between 0.2 and 2, a median coefficient of variation of coverage of the 1000 most expressed genes below 0.8, a free-mix value below 0.05. Lastly, we removed samples that had low expression correlations (<0.6) to the average iPSC expression values across our study, as measured per chromosome. This resulted in 1,367 iPSC lines derived from 948 donors for analysis, all of which also have genetic information available. Next to this we had 98 samples from Choi et al 13 and HipSci 9,43 which are included as reference (table S2) .
After RNA QC the sample linking was validated using VerifyBamID, for each of the RNA-samples the best matching genotype were computed and compared to the expected match. This resulted in the identification of 36 sample mixups (between 0-26 mismatches per study), and identified in total 33 unmatched RNA-seq samples. Some of the mix-ups were corrected (N=34) and others were removed (N=2).
PEER correction and optimization
We correct for transcriptome-wide confounders arising from the merging of multiple datasets, to do so we chose to estimate PEER 21 factors to capture these confounders. We chose not to include any known variation when estimating PEER factors, as meta-data was sparse and not standardized between studies. We ran PEER (v1.3) on the log-transformed gene-level quantifications, on genes that had a TPM > 2. We assessed the impact of the number of PEER factors on eQTL mapping in our data by calculating the number of eGenes (at least one eQTL at FDR < 5%) with incrementally increasing number of PEER factors (Figure S9) . We chose to use 50 PEER factors to correct for confounders in out data. Assuming trans-eQTL impacting many transcripts may be included as latent factors in PEER analyses, we then tested eQTL effects against each of the 50 PEER factors. We did not find any likely trans-eQTL-associated PEER factors.
Quantitative trait loci mapping
For the quantitative trait loci mapping (QTL) mapping, both the cis and trans, we used a linear mixed model implemented in LIMIX 68 . This model allowed to control for both population structure and repeat lines from the same donor using kinship as a random effect component. The kinship matrix was estimated using the identity-by-descent function in PLINK (1.07) 69 , on independent variants with a MAF >5%. Fifty PEER factors, derived on the gene-level data were included as fixed effect covariates in all analyses, optimization is described above. The QTL mappings are performed on the log transformed standardized expression levels in case of the gene-level and exon-level data; for the other expression phenotypes, the ratio based phenotypes, we used an arcsin-transformation.
To control for multiple testing we used an approximate permutation scheme as presented in Fast-QTL 70 
cis-eQTL Mapping
During the mapping of cis-quantitative trait loci (cis-QTL), we considered common variants (MAF>1%) in gene-proximal regions of 250k upstream and downstream of gene transcription start and end sites (GRCh37). We limited the analysis to include only paired-end stranded European samples, as determined from the super population assignment, (n=716 donors, n=932 lines) to limit variation between trait discovery and to have the same discovery sample size in all cis-QTL maps. We controlled for multiple testing at a gene-level FDR of < 5% for the cis-QTL maps.
For the different expression phenotypes, we tried to use matched inclusion criteria. We limited the analysis to features that were expressed, i.e. non-zero expression, in at least 25% of the samples. For the splicing and APA-QTL we required at least 50% of the samples to have a nonzero and non-NA ratio, the assessed genes per QTL type is summarized in Table S15 .
After identification of the lead cis-eQTL for the gene-level effects, we searched for independent eQTL (secondary eQTL and higher order effects). For each of the significant eQTL gene the significant eQTL variant(s) from lower levels were added as a covariate to the model and a new QTL mapping round was run to identify independent cis-QTL. This search for independent effects was continued for each gene until no more independent cis-eQTL were identified.
Trans-eQTL mapping
During the mapping of trans-quantitative trait loci (trans-eQTL), we considered common variants (MAF>1%) in gene-distal regions defined as at least 2.5M upstream and downstream of the gene transcription start and end sites (GRCh37). Given the large number of tests in a full trans-map, we chose to limit the trans-eQTL map to both cis-QTL variants and GWAS implicated variants.
This limited the number of variants that had to be tested to 115,709. In addition, we only considered protein coding genes with a TPM ≥ 1 (n=17,039) and expressed in at least 25% of the samples. Other settings were matched to those described above. However, to limit the chance of spurious associations we included an extra expression normalization step -we quantile normalized the normalized gene counts to match a normal distribution. During the trans-QTL phase we switched to using all samples with European ancestry (n=743, lines=1,120) as we only looked at gene-level effects.
To further limit the chance of spurious associations, specifically those linked to cross-mapping of RNA-reads 72 , we set out to black-list combinations of genes a-priori. We created a black-list by using the information contained in the mapping of the RNA reads to the genome, i.e. using primary and secondary genome matches. The gene-level quantifications are based only on the primary mapping of a read but the secondary mappings that do pass the mapping thresholds are informative to identify genes with high sequence similarity. A benefit of this approach is that it is directly based on the reads that we also use for gene quantification and is influenced by the same biases. We built this cross-mapping map using all the paired end stranded data. When a gene combination would be in the black list we also removed the trans-window around the secondary gene from the test region. We also excluded the HLA region, due to its complex LD structure.
cis-eQTL annotation
The i2QTL genetic maps where annotated by overlapping the QTL signals with information taken from published QTL maps, gathered from the original iPSC studies 7-10,45 , GTEx 5 and BIOS 4 .
To assess the replication of the eQTL effects published in the original iPSC studies 7-10,45 , we tested for replication of the published eQTL effects at p-value<0.05 and assessed effect direction ( Fig. S1-4) . The original QTL maps were taken as provided, i.e. replication was assessed based on the published significance levels. When assessing the replication within the iPSCORE study we focused only on the effects attributed to SNPs, and excluded the effects of structural variants.
Between 75% and 82% of the effects were assessed in both the original study and the i2QTL study, replication rates of the effects that are between 62% and 86% ( Fig. S1-4 ).
Using the GTEx 5 and BIOS 4 QTL maps we assessed the overlap of eGenes to identify effects specific to iPSC. Effects from the original studies where taken as provided, i.e. FDR 5% as calculated in the studies. Next we assessed replication in terms of eGenes within the individual tissues (Fig 1B) as well as looking at eGenes in any of the GTEx tissues or BIOS (Fig 1B-1C) .
To test for similarity between genetic effects observed at the different gene expression phenotypes, we assessed replication between the signals at the different levels. The overlap was assessed for individual eQTL, i.e. SNP-gene combinations, by mapping the different QTL types to the respective gene of the effect and taking the most significant association (at gene-level FDR)
if multiple were tested per gene. If the effect present at the first QTL type was replicated at FDR 10% in a second QTL type this was counted as a replicating effect (Fig 1E) .
Replication of trans-eQTL
Using the expression samples from other inferred super populations (n=186 donors, n=253 lines) Table S2 , we could assess replication of the trans-eQTL. Next to this we used DNA-methylation data available in a subset (n=572 donors, n=841 lines) to do cross-omic replication of the identified trans-eQTL.
The replication of the trans-eQTL in the left out expression data was performed using the same setup as for the main trans-eQTL analysis, with the exception of the PEER factor correction. To not induce effects based on PEER factors, we chose to only correct for the limited known factors across our datasets: inferred ancestry, sequencing type (paired-end (yes/no), stranded (yes/no)) and hot encoded vectors describing the dataset of origin. We deemed trans-eQTL as replicated in the left-out samples when the raw p-value of the association was below 0.05 & the effect direction was matching to the effect observed in the trans-eQTL map.
The replication within the DNA-methylation data was similarly matched as closely as possible.
We started with a joint normalization of the Banovich et al 8 and HipSci 9,43 DNA-methylation arrays.
As the data was generated on two different Illumina methylation arrays, the Illumina 450K and
Illumina EPIC array, we started with sub-selecting the CpG probes that are present on both. After this we normalized the DNA-methylation profiles, as described in detail Bonder et al 3 , based on the DASEN 73 normalization. After joint normalization, we correct the data for the first 20 PCs to account for batch effects in the DNA-methylation data. In order to replicate the trans-eQTL in DNA-methylation data, we first had to link CpG probes to genes. We chose to do so by linking a gene to all DNA-methylation probes inside the gene and CpG probes that are within within 250Kb of the gene TSS and TES. Given that we test a multitude of CpG's per trans-eQTL gene we determine the number of independent DNA-methylation probes per gene (R2<0.2) and used Bonferroni procedure to correct for the number of independent probes that were tested per gene.
We deemed trans-eQTL as replicated in DNA-methylation when the CpG corrected replication pvalue was below 0.05.
To check if we replicate more effects than expected by chance, we repeated the trans-eQTL and trans-meQTL replication on random trans-eQTL pairs. To try and match the trans-eQTL characteristics, we chose to link the trans-eQTL variant to a gene with matched expression characteristics, by selecting the ten genes per trans-gene with the closest average and variance levels. The same random pairs were used for the trans-meQTL replication.
Outlier analysis
In addition to variation linked to common variants (MAF >1%), rare variants were linked to transcriptomic outliers. Using the featureCount gene quantifications (log TPM), genes were subset to only include autosomal protein-coding and long non-coding RNA genes. Cell lines from donors with predicted ancestry other than European super-population were removed, and only paired-end stranded cell lines were selected. Genes were then filtered for minimal expression, defined as gene expression TPM>0 in 50% or more within each study.
To correct for technical effects, PEER 21 factor correction was run on the filtered data as described above. Following the correction of 50 PEER factors, as chosen based on the cis-eQTL PEER optimization, the resulting residuals were scaled and centered (Z-score). Samples were then checked for large gene outlier counts (i.e. cell line is found to be the most under-or overexpressed cell line across hundreds of genes), which suggests possibly incomplete correction for technical effects. Cell lines with expression abs(Z-score)>2 in more than 100 genes were removed from subsequent analysis (N=21 lines). Finally, cell lines were retained only if WGS was available in addition to RNA-seq, leaving data from the HipSci and iPSCORE projects only. After applying these steps, 17,514 genes and 425 cell lines remained in the dataset for further analysis.
To prepare the WGS genotype data SNP and indel variants for the analysis, variants were first filtered based on QVSR tranche 99%. The software vcfanno 74 
Outlier enrichment
An enrichment score was calculated to quantify the difference in proportions of outlier lines with variants across several MAF/CADD bins compared with non-outlier lines. Specifically, enrichment here refers to the relative risk:
, where is the number of outlier lines with >=1 variant in or near (+/-10 Kb upstream or downstream of gene body) a gene passing given MAF and CADD thresholds, is the total number of outlier lines, ′ is the number of non-outlier lines with >=1 variant in/near gene passing given MAF and CADD thresholds, and ′ is the number of non-outlier lines. The relative risk is reported with 95% Wald confidence intervals derived from the asymptotic distribution of the log relative risk:
The bounds on the confidence interval are defined as follows:
The analysis was performed separately for SNP, indel, SV variants, and across different MAF bins (from common to rare) and CADD bins (progressively more deleterious variants). Expression outlier direction (i.e. under-expression, over-expression) was tested separately. For example, for under-expression outliers, an outlier line was defined as the least-expressed line in a given gene that also has a Z-score < -2. In this way, a gene can have a maximum of one outlier line per outlier direction. Non-outliers were defined as lines with a Z-score between -1 and 1 for a given gene.
Genes were discarded if there was not at least one outlier and one non-outlier line matching MAF and CADD thresholds. The outlier analysis was performed for both i2QTL and GTEx datasets.
Colocalization of GWAS loci with iPS QTL
To choose the combinations of loci, features, and traits at which to test for colocalization, we started with two sets of curated GWAS summary stats: one including UK Biobank (UKBB) rapid GWAS results (for 1,740 traits) (cite Neale et al.), and the other including publicly available GWAS results gathered from the NHGRI-EBI GWAS catalog 22 and PHENOMESCANNER V2 34 for 303 studies, obtained through a wide variety of studies and consortia 35 . For every trait in this set, we selected loci having a GWAS association a p-value of < 5x10^-8 and located at least 1Mb away from all previously selected (more significant) loci for the same GWAS trait. We further narrowed this set of GWAS-relevant loci to with a significant cis-QTL, for any of the quantified expression phenotypes, within 10kb of the lead GWAS hit at a gene-level corrected FDR of less than 5%.
Due to the vast number of SNPs and traits in the UKBB, we only tested UKBB GWAS hits for colocalization if the lead GWAS hit overlapped exactly with a known eQTL, for computational feasibility. The resulting loci comprised our colocalization test set, to be tested for colocalization with every eQTL phenotype having a significant association nearby. Given the presence of several different types of eQTL and abundant measured features for each of these eQTL types, it was possible for a single GWAS locus to be tested for colocalization with a number of QTL traits originating from single or multiple genes.
We then tested every resulting pair of GWAS locus and eQTL feature in our set. For each of these pairs, we narrowed our summary statistics to the set of SNPs tested for association with both the given GWAS trait and the given eQTL trait, and removed all sites containing less than 5 SNPs after this filter. Using the full 1000 Genomes dataset from phase 3 (2,504 individuals) as a reference population 48 , we estimated LD between all of these SNP pairs. We then ran FINEMAP 32 independently on the GWAS and eQTL summary stats to obtain posterior probabilities of causality for each of the remaining SNPs, and we combined these probabilities to compute a colocalization posterior probability (CLPP) using the formula described in the eCAVIAR method 32, 33, 35 .
Given the imperfect overlap between the variants in the GWAS summary statistics and the QTL data it can happen that the minimal corrected eQTL p-value or the GWAS p-values in a locus, after subsetting, were higher than the initial inclusion criteria of a locus. To exclude colocalizations in loci where only a very weak association, at either or both statistics, is observed, we excluded tests where the minimal GWAS p-value in the overlapping locus was higher than 5e-6 or the genelevel corrected eQTL p-value was greater than 0.05. We considered a locus to be colocalized if it passed one of three CLPP thresholds; 1) minimal 5 variants with a CLPP of 0.5; 2) minimal 10 variants and a CLPP of 0.1; or 3) minimal 25 variants with a CLPP of 0.01.
Annotating i2QTL rare variants using UKBB GWAS summary statistics
To test for differences in outlier and non-outlier associated rare variants and risk for disease and traits, we overlapped i2QTL WGS variants (as described in Outlier Analysis above) with those measured or imputed in UKBB GWAS 77 . Specifically, we looked at variants with gnomAD MAF<1% and CADD>0. Multi-allelic variants were discarded. Variants were retained if they were observed in only one i2QTL individual, with the hypothesis being that these variants are driving observed outlier effects. From this list of unique variants (i.e. observed in only one i2QTL sample), outlier-associated variants were found separately for under-expression and over-expression outlier samples (therefore, there could be a maximum of two outlier samples per gene).
For each gene with >= 1 outlier sample, non-outlier-associated variants were chosen for each non-outlier sample if a variant had a CADD score within a range +/-5 of outlier variants. A nonoutlier sample was defined as a sample with expression Z-score > -1 and <1 for a given gene. If a non-outlier sample had a greater number of variants than the outlier sample, variants were randomly downsampled to match the number of outlier variants. If a non-outlier sample had a less or equal number of variants than the outlier sample, all variants were chosen for that sample. This process was performed separately for each gene and each outlier direction (i.e. under-expression, over-expression). The final list of variants was linked to UKBB GWAS effect size and p-values for each trait in UKBB GWAS Phase 1.
Data availability
All data used in the study is available via SRA, dbGaP or ENA; the full data availability is provided in Table S1 . Table S2 provides sample description on the samples used in the study.
